J6M0-mcMMAF rapidly eradicates MM tumors established in mice and significantly prolongs survival. (A) SCID mice with palpable H929 tumors (∼150 mm3) were randomized into groups (n = 5 each) and then treated twice weekly for 4 total doses by intraperitoneal injection. (B) SCID mice with palpable OPM2 tumors were randomized into groups (n = 5 each) and then treated twice weekly for a total of 2 or 4 doses by intraperitoneal injection. (C) NK-deficient SCID-beige mice were inoculated IV with MM1Sluc cells. At a mean bioluminescence (BLI) of 3E ± 06 indicating MM1Sluc tumor growth, mice were randomized into groups (n = 8 each) and treated with J6M0-mcMMAF, J6M0, iso-mcMMAF, or vehicle (PBS), twice weekly for a total of 9 doses by intraperitoneal injection. Survival of mice was examined using log-rank (Mantel-Cox) analysis. *P < .0002.
